经典致幻剂研究中的不良事件:系统综述与荟萃分析
该系统综述与荟萃分析检索了Scopus、MEDLINE、PsycINFO和Web of Science至2024年2月8日的文献,纳入214项经典致幻剂研究,其中114项(53.3%)报告了3504名参与者的可分析不良事件数据。严重不良事件在健康参与者中未见报告,在既往有神经精神障碍的参与者中约4%报告,需医疗干预的非严重不良事件同样罕见;但不良事件监测与报告质量存在显著异质性。
要点
- 健康参与者中未报告严重不良事件,既往有神经精神障碍者约4%报告严重不良事件。
- 当代研究背景下,高剂量经典致幻剂给药后未报告自杀死亡、持续性精神病性障碍或致幻剂持续感知障碍。
- 2005年以来68项分析研究中仅16项(23.5%)描述系统性不良事件评估方法,20项(29.4%)报告所有不良事件。
核心结论
- 根据现有文献,经典致幻剂在临床或研究环境中总体耐受性良好,但严重不良事件确有发生。
- 这些结果提供了常见不良事件频率的估计,并表明娱乐性或非临床环境中报告的某些灾难性事件在当代试验参与者中尚未见报告。
- 需要审慎、持续且改进的药物警戒,以了解这些物质的风险获益特征并向潜在研究参与者和公众传达这些风险。
研究设计与样本
- 系统综述与荟萃分析,检索Scopus、MEDLINE、PsycINFO和Web of Science数据库自建库至2024年2月8日的文献。
- 两位独立评审者筛选涉及经典致幻剂(LSD、裸盖菇素、DMT和5-MeO-DMT)在临床或研究环境中给药的研究。
- 不良事件数据由2位评审者提取,用于不良事件频率和异质性的随机效应荟萃分析。
- 偏倚风险评估聚焦于不良事件确认(如系统性评估和随访质量)。
主要发现
- 共纳入214项独特研究,其中114项(53.3%)报告了3504名参与者的可分析不良事件数据。
- 健康参与者中未报告严重不良事件;既往有神经精神障碍的参与者中约4%报告严重不良事件,包括抑郁加重、自杀行为、精神病和惊厥发作。
- 需医疗干预的非严重不良事件(如偏执、头痛)同样罕见。
- 当代研究环境中,高剂量经典致幻剂给药后未报告自杀死亡、持续性精神病性障碍或致幻剂持续感知障碍。
- 2005年以来发表的68项分析研究中,仅16项(23.5%)描述系统性不良事件评估方法,20项(29.4%)报告所有不良事件而非仅药物不良反应。
关键数值与推荐
- 常见不良事件(如头痛、焦虑、恶心、疲劳和头晕)的患病率荟萃分析显示裸盖菇素和LSD结果相当。
- 严重不良事件在健康参与者中未见报告,在既往有神经精神障碍的参与者中约4%报告。
临床怎么用
- 原文未据此给出推荐。
局限性
- 不良事件监测和报告质量存在显著异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its application to new populations and indications. OBJECTIVE: To assess adverse events (AEs) associated with classic psychedelics, particularly serious AEs (SAEs) and nonserious AEs (NSAEs) requiring medical or psychiatric evaluation. DATA SOURCES: The search for potentially eligible studies was conducted in the Scopus, MEDLINE, PsycINFO, and Web of Science databases from inception through February 8, 2024. STUDY SELECTION: Two independent reviewers screened articles of classic psychedelics (lysergic acid diethylamide [LSD], psilocybin, dimethyltryptamine [DMT], and 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT]) involving administration in clinical or research contexts. DATA EXTRACTION AND SYNTHESIS: AE data were extracted and synthesized by 2 reviewers and were used for random-effects meta-analysis of AE frequency and heterogeneity. Risk of bias assessment focused on AE ascertainment (eg, systematic assessment and quality of follow-up). MAIN OUTCOMES AND MEASURES: A hybrid approach was used for capture of all reported AEs following high-dose classic psychedelic exposure and confirmatory capture of AEs of special interest, including suicidality, psychotic disorder, manic symptoms, cardiovascular events, and hallucinogen persisting perception disorder. AEs were stratified by timescale and study population type. Forest plots of common AEs were generated, and the proportions of participants affected by SAEs or NSAEs requiring medical intervention were summarized descriptively. RESULTS: A total of 214 unique studies were included, of which 114 (53.3%) reported analyzable AE data for 3504 total participants. SAEs were reported for no healthy participants and for approximately 4% of participants with preexisting neuropsychiatric disorders; among these SAEs were worsening depression, suicidal behavior, psychosis, and convulsive episodes. NSAEs requiring medical intervention (eg, paranoia, headache) were similarly rare. In contemporary research settings, there were no reports of deaths by suicide, persistent psychotic disorders, or hallucinogen persisting perception disorders following administration of high-dose classic psychedelics. However, there was significant heterogeneity in the quality of AE monitoring and reporting. Of 68 analyzed studies published since 2005, only 16 (23.5%) described systematic approaches to AE assessment, and 20 studies (29.4%) reported all AEs, as opposed to only adverse drug reactions. Meta-analyses of prevalence for common AEs (eg, headache, anxiety, nausea, fatigue, and dizziness) yielded comparable results for psilocybin and LSD. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, classic psychedelics were generally well tolerated in clinical or research settings according to the existing literature, although SAEs did occur. These results provide estimates of common AE frequencies and indicate that certain catastrophic events reported in recreational or nonclinical contexts have yet to be reported in contemporary trial participants. Careful, ongoing, and improved pharmacovigilance is required to understand the risk and benefit profiles of these substances and to communicate such risks to prospective study participants and the public.
引用
- Hinkle JT, Graziosi M, Nayak SM, et al. Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry. 2024. PMID: 39230883. doi:10.1001/jamapsychiatry.2024.2546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。